Lazard Asset Management LLC Decreases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Lazard Asset Management LLC cut its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) by 50.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,748 shares of the specialty pharmaceutical company’s stock after selling 1,750 shares during the quarter. Lazard Asset Management LLC’s holdings in Supernus Pharmaceuticals were worth $59,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Nuveen Asset Management LLC increased its position in shares of Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Nuveen Asset Management LLC now owns 373,509 shares of the specialty pharmaceutical company’s stock valued at $12,643,000 after purchasing an additional 18,950 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Supernus Pharmaceuticals in the 3rd quarter worth about $1,229,000. Altshuler Shaham Ltd purchased a new stake in Supernus Pharmaceuticals in the 3rd quarter worth about $59,000. Hsbc Holdings PLC increased its holdings in Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Hsbc Holdings PLC now owns 23,196 shares of the specialty pharmaceutical company’s stock worth $791,000 after acquiring an additional 5,344 shares during the last quarter. Finally, Pictet Asset Management SA increased its holdings in Supernus Pharmaceuticals by 27.0% in the 3rd quarter. Pictet Asset Management SA now owns 163,848 shares of the specialty pharmaceutical company’s stock worth $5,546,000 after acquiring an additional 34,784 shares during the last quarter. 99.82% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 11,354 shares of the firm’s stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $38.14, for a total transaction of $433,041.56. Following the transaction, the chief executive officer now directly owns 814,699 shares of the company’s stock, valued at approximately $31,072,619.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Jack A. Khattar sold 11,354 shares of Supernus Pharmaceuticals stock in a transaction on Wednesday, December 21st. The shares were sold at an average price of $38.14, for a total value of $433,041.56. Following the transaction, the chief executive officer now directly owns 814,699 shares of the company’s stock, valued at $31,072,619.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jack A. Khattar sold 25,446 shares of the firm’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $40.03, for a total transaction of $1,018,603.38. Following the completion of the sale, the chief executive officer now directly owns 791,173 shares in the company, valued at approximately $31,670,655.19. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,308 shares of company stock valued at $2,261,264. Corporate insiders own 8.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. TheStreet raised Supernus Pharmaceuticals from a “c+” rating to a “b+” rating in a report on Tuesday, February 28th. Piper Sandler raised their target price on Supernus Pharmaceuticals from $40.00 to $47.00 and gave the stock an “overweight” rating in a research note on Monday, January 23rd. Finally, StockNews.com downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday.

Supernus Pharmaceuticals Trading Down 0.1 %

Shares of SUPN opened at $38.36 on Wednesday. The company has a market cap of $2.07 billion, a PE ratio of 37.24 and a beta of 1.01. The stock has a 50-day moving average price of $39.19 and a 200-day moving average price of $36.20. Supernus Pharmaceuticals, Inc. has a 12-month low of $24.95 and a 12-month high of $42.09.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last issued its quarterly earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.30). The business had revenue of $167.33 million for the quarter, compared to the consensus estimate of $180.38 million. Supernus Pharmaceuticals had a net margin of 9.10% and a return on equity of 7.12%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.04 EPS. As a group, analysts predict that Supernus Pharmaceuticals, Inc. will post 0.66 earnings per share for the current year.

Supernus Pharmaceuticals Company Profile

(Get Rating)

Supernus Pharmaceuticals, Inc engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.